Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Nedaplatin (formerly NSC-375101D; NSC 37510D; NSC-375101 D; NSC 375101-D; trade name Aqupla) is a cisplatin analog and DNA damaging agent approved as an anticancer medication. At 94 μM, it inhibits the formation of tumor colonies. Nedaplatin is a platinum compound used in cancer chemotherapy; however, compared to other drugs containing platinum, it has fewer side effects, including nephrotoxicity, nausea, and vomiting.
Targets |
DNA synthesis
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Cell Assay |
An assay for regrowth is used to measure the antitumor activity of the drug treatments, which include the inhibition of cell proliferation (including that of human SCLC cell line SBC-3 and human NSCLC cell line PC-14). To put it briefly, cells are treated with drugs alone or in combination for six days at 37°C in a 100% humidity and 5% CO2 environment. After that, the cells are pipetted six to eight times, or nearly all of them become single cells, and they are counted using a counter. Plotting the percentage of surviving cells (the unaffected cell fraction, fu) against drug concentration yields concentration-effect curves for each drug. To calculate the treated:control cultures' cell proliferation ratio (T:C%), use the formula below: [(the number of treated cells on day 6)/(the number of treated cells on day 0)]/[(the number of control cells on day 6)/(the number of control cells on day 0)] × 100%. The drug concentration needed to cause a 50% decrease in the number of cells is known as the IC50. For each, four or five separate experiments are conducted. In order to assess the impact of the drug treatment schedule on the combination's effect, the cells are treated for three hours either sequentially—first with Nedaplatin and then with irinotecan (Nedaplatin→irinotecan) or simultaneously with both drugs. Cells are exposed to the first drug for three hours during the sequential exposure treatment, then they are immediately exposed to the second drug for three hours after being ished in fresh medium once. Up until assessment, the treated cells are cultivated in a drug-free medium.
|
|
Animal Protocol |
Tumor-bearing athymic BALB/c nude mice with Ma44 or NCI-H460 cells
10 mg/kg or 20 mg/kg Administered via i.v. |
|
References |
Molecular Formula |
C2H8N2O3PT
|
|
---|---|---|
Molecular Weight |
303.17
|
|
Exact Mass |
303.02
|
|
Elemental Analysis |
C, 7.98; H, 2.01; N, 9.30; O, 15.94; Pt, 64.78
|
|
CAS # |
95734-82-0
|
|
Appearance |
Solid powder
|
|
SMILES |
C(C(=O)O)O.N.N.[Pt]
|
|
InChi Key |
ZAXCMPAWRCMABN-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C2H4O3.2H3N.Pt/c3-1-2(4)5;;;/h3H,1H2,(H,4,5);2*1H3;
|
|
Chemical Name |
azane;2-hydroxyacetic acid;platinum
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.2985 mL | 16.4924 mL | 32.9848 mL | |
5 mM | 0.6597 mL | 3.2985 mL | 6.5970 mL | |
10 mM | 0.3298 mL | 1.6492 mL | 3.2985 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04212052 | Active Recruiting |
Radiation: split-course radiotherapy Drug: concurrent chemotherapy |
Non-small Cell Lung Cancer | Sun Yat-sen University | December 1, 2019 | Phase 2 |
NCT02279134 | Active Recruiting |
Drug: Cisplatin or Nedaplatin Drug: Paclitaxel |
Esophageal Cancer Esophageal Neoplasms |
Zefen Xiao | October 2014 | Phase 2 Phase 3 |
NCT04437329 | Recruiting | Drug: Nedaplatin Drug: Cisplatin |
Nasopharyngeal Carcinoma | Affiliated Cancer Hospital & Institute of Guangzhou Medical University |
August 1, 2020 | Phase 3 |
NCT05039606 | Not yet recruiting | Drug: Nedaplatin Drug: Cisplatin |
Head and Neck Squamous Carcinoma | Guiyang Medical University | September 2021 | Phase 2 |
NCT04844385 | Recruiting | Drug: Nedaplatin Radiation: SMART |
Esophageal Squamous Cell Carcinoma |
Sun Yat-sen University | February 20, 2021 | Phase 2 |